


Pfizer's BNT162b2 and Women's Health

Robert W. Chandler MD MBA

1

1. Why I got Involved
2. Pfizer Documents Analysis Project (PDAP)
3. Female: Male Adverse Event Differences
4. CoVax Disease



Part 1: Why? State of Mind Jan-Mar 2021

2

Injected with every vaccine including those for travel in Africa, Peruvian Amazon, and Remote Pacific Islands

1. Bias in Favor of Vaccines
2. I researched the C19 medical literature (from China), Nursing Home in Pacific Northwest, Diamond Princess, Bhattacharya Paper
3. **Conclusion: Despite co-morbidities my personal risk was very low**

I had no Distrust of Pharma

- I had been a Clinical Investigator for Pfizer Company, Howmedica
- Information available was that LNP/mRNA remained in deltoid tissues and had half life of 12 hours

Our Grandchildren were afraid they would make us sick!


I had Trust in the FDA and CDC



mRNA1273 and Dodger Stadium Parking Lot 1/21/2021 & 2/18/2021

3

Dose 2 mRNA1273 022m20A




18 hrs. Post Injection for 14 hours:
Lassitude, Fatigue, Nausea, Loss of Appetite, Myalgia
Mental Fogginess, Rapid Fever Elevation

4


36,768 Administrative Errors

Ages 0 - 17



Ongoing mRNA1273 Related Medical Issue?

1. Free Light Chains are Elevated in a diversity of medical conditions
2. Most Concerning are Plasmacytoma and Multiple Myeloma
3. 77 Cases of Free Light Chain Elevations or Tissue Deposition confirmed by biopsy in VAERS.




Aaron Siri Prevailed in His Freedom of Information Request and Lawsuit

7

News ▾ Podcasts Research Tools ▾ Bloomberg Law Log In Sign Up For N


Health Law & Business



Photographer: Sarah Silbiger/Getty Images

Jan. 18, 2022, 1:00 AM PST

Why a Judge Ordered FDA to Release Covid-19 Vaccine Data Pronto

 **Aaron Siri**
Siri & Glimstad

In response to a Freedom of Information Act request, the Food and Drug Administration asked a federal judge for permission to make the public wait until the year 2096 to disclose all of the data it relied upon to license Pfizer's Covid-19 vaccine.

The agency originally estimated it would need to produce 329,000 pages, and asked the court for permission to produce just 500 pages per month, which would have taken 55 years. In its final brief to the Court, the FDA admitted that the total page count was at least 451,000, but still sought permission to produce just 500 pages per month. Meaning that it could have taken 75 years, when most Americans alive today would be dead, to fully publicly disclose this information.

On Jan. 6, a federal court in the Northern District of Texas ordered the expedited release. As of Jan. 12, the FDA hasn't indicated it intends to appeal.

My Assumption was that it would not take long to verify the work done to develop and market BNT162b2 was done properly.

Project Structure:



Six Teams Weekly Meeting of All Teams (Unpaid Volunteers)



Weekly Meeting of Each Team



Documents Distributed According to Skill sets

PDAP Processes:

- A. Document and Data Acquisition
- B. Distribution
- C. Collaboration
- D. Add On Resources

Public Health and Medical Professionals for Transparency Documents

Pfizer 16+ Court Documents

Search:

[Reset](#)

20 documents

| File Name | Date Produced | File Size | Link |
|---|------------------|-----------|---|
| 034 - Transcript of Scheduling Conference (December 14, 2021).pdf | March 16, 2022 | 141 KB | Download <input type="checkbox"/> |
| Order February 7, 2022.pdf | February 7, 2022 | 151 KB | Download <input type="checkbox"/> |
| 056 - ORDER GRANTING IN PART THE MOTION TO MODIFY THE PRODUCTION SCHEDULE AND ADDOPTS THE JOINT STATUS REPORT MODIFIED AGREED PRODUCTION SCHEDULE.pdf | February 2, 2022 | 124 KB | Download <input type="checkbox"/> |
| 047 - PLAINTIFF'S RESPONSE TO PFIZER INC.'S MOTION FOR LEAVE TO INTERVENE FOR A LIMITED PURPOSE.pdf | January 25, 2022 | 293 KB | Download <input type="checkbox"/> |
| 046 - RESPONSE filed by Food and Drug Administration re [40] MOTION to Intervene for a Limited Purpose.pdf | January 25, 2022 | 128 KB | Download <input type="checkbox"/> |
| 044 - PL PHPMT'S MOL IN OPPOSITION TO DEFENDANT'S MOTION TO MODIFY THE SCHEDULING ORDER OF THE COURT.pdf | January 24, 2022 | 420 KB | Download <input type="checkbox"/> |
| 041 - Memorandum in Support filed by Pfizer, Inc. re [40] MOTION to Intervene for a Limited Purpose.pdf | January 21, 2022 | 1,014 KB | Download <input type="checkbox"/> |

PDAP Output After 2 Years



98 Reports: DailyClout.io



1 Peer Reviewed Paper

<https://ijvtpr.com/index.php/IJVTPR/article/view/86>



Hundreds of Internet Postings (Substack)





2 Books



Numerous Media Presentations

Q: Did They Release Everything? A: No

11



Redactions

Millions of Missing Lab Values

| <u>Subjects</u> | <u>40,000</u> |
|--------------------------|---------------|
| 5 tubes/draw | 200,000 |
| 3 draws | 600,000 |
| 3 tests/tubes (estimate) | 3,000,000 |
| 5 tests/tubes (estimate) | 6,000,000 |

Of Specific Interest: Lymphocyte Counts, Cytokines, HCG

Part 3: Female Male Differences

Findings To Be Discussed Sources: Pfizer Documents, Govt Databases, Scientific Literature, and Burkhardt/Lang IHC Data

12

Levels of Evidence Paradigm



https://www.researchgate.net/figure/Hierarchy-of-evidence-pyramid-The-pyramidal-shape-qualitatively-integrates-the-amount-of_fig1_311504831

- Flaws in Phase 2/3 Randomized Double Blinded Controlled Trial
 - Unblinded Control Group @ a few mos. Not 2 years
 - Protocol Deviations
 - Superficial Data Collection
- No Prospective Cohort Studies
- Limited Retrospective and Observational Studies
- Limited Autopsy Data
 - Rare Histopathology + Immunohistochemistry
 - Burkhardt/Lang Series of 169 Cases an Exception

LNP/mRNA Genetic Platform Flaws

13

(Sahin, et al., 2014, Weissman, et al., 2018, Granot-Matok, et al., 2019)

- Duration and Mode of Action
 - modRNA
 - Translated proteins
- Non-self proteins and autoimmunity
- Stem cell alteration
- Biodistribution
- Metabolites: Amyloid
- Accumulated Dose Effects
- Cytokinopathy
- Dysregulation of host genome including oncogenes
- • Immune suppression (VAIDS and IgG₄)
- Altered Coagulation Kinetics and Morphology

Useful Summary Reports : 2.4 and 5.3.6

Report 81: Summary of 2.4 Nonclinical Overview – Pfizer mRNA COVID-19 Vaccine, BNT162b2

August 29, 2023 • by Robert W. Chandler, MD, MBA

Reference document Pfizer confidential document "2.4 NONCLINICAL OVERVIEW," Version 3 (36 pages) while reading this summary. [
https://phmpt.org/wp-content/uploads/2022/03/125742_S1_M2_24_nonclinical-overview.pdf]

Not Studied:

1. Secondary pharmacodynamics. P14¶1
2. **Safety pharmacology:** "No safety pharmacology studies were conducted with BNT162b2 as they are not considered necessary for the development of vaccines according to the WHO guideline (WHO, 2005)." P.14¶2
3. **Pharmacodynamic Drug Interactions:** "Nonclinical studies evaluating pharmacodynamic drug interactions with BNT162b2 were not conducted as they are not generally considered necessary to support development and licensure of vaccine products for infectious diseases (WHO, 2005)." P14¶3.
4. **No pharmacokinetic studies were performed with BNT162b2 and "...are generally not considered necessary to support the development and licensure of vaccine products for infectious diseases (WHO, 2005, WHO, 2014)." P17¶1.**
5. **"The protein encoded by the RNA in BNT162b2 is expected to be proteolytically degraded like other endogenous proteins. RNA is degraded by cellular RNases and subjected to nucleic acid metabolism. Nucleotide metabolism occurs continuously within the cell, with the nucleoside being degraded to waste products and excreted or recycled for nucleotide synthesis. Therefore, no RNA or protein metabolism or excretion studies will be conducted."** P20¶3
6. **Genotoxicity:** "No genotoxicity studies are planned for BNT162b2 as the components of the vaccine construct are lipids and RNA are not expected to have genotoxic potential (WHO 2005)." P29 ¶3.
7. **"Carcinogenicity studies with BNT162b2 have not been conducted as the components of the vaccine are lipids and RNA and are not expected to have carcinogenic or tumorigenic potential."** P29 ¶4. (WHO 2005)
8. **Phototoxicity. P30.**
9. **Mechanistic studies. P30.**
10. **Target organ toxicity:** "Based on data from the GLP repeat-dose toxicity studies, administration of BNT162b2 was well tolerated without any evidence of systemic toxicity." P31 ¶5.
11. **Dependence. P31.**
12. **Metabolites. P31.**
13. **Impurities. P31.**
14. **Microanatomy studies of blood vessels, heart, lungs, and brain are not documented.**
15. **Biodistribution of mRNA was not specifically studied.**
16. **Biodistribution and toxicity studies of mRNA S protein were not referenced.**

Experimental Gene Therapy

Pfizer Document 5.3.6 Reissue: Adverse Events

Cumulative Analysis of Post-authorization Adverse Event Reports Through 28-Feb-2021, Tables 1-7

ROBERT W. CHANDLER, MD MBA
JUN 30, 2022


Cumulative Analysis of Post-authorization Adverse Events Through 2/28/2021
Tables 1-6 AES

"Relevant" Adverse Events: Subjects

| Table 1 | | N = | |
|-----------------------|--------------------------|--------------|-----|
| Gender | F | 29914 | 71% |
| | M | 9182 | 22% |
| | ND | 2990 | 7% |
| | Total | 42086 | |
| Age | <12 | 34 | |
| | <16 | 46 | |
| | ≤ 17 | 95 | |
| | 18-30 | 4953 | |
| | 31-50 | 13886 | |
| | 51-64 | 7884 | |
| | 65-74 | 3098 | |
| | ≥75 | 5214 | |
| | Ukn | 6876 | |
| | Total | 42086 | |
| Outcome | | N = | |
| *Of (total)-(unknown) | Recovered/Recovering* | 19582 | 60% |
| *Of (total)-(unknown) | Not recovered* | 11361 | 35% |
| Of 42,086 | Unknown* | 9400 | 22% |
| | Fatal* | 1223 | 4% |
| Of (total)-(unknown) | Recovered with sequelae* | 520 | 2% |



Pfizer Document 5.3.6: Data Collection Completed 2/28/2021

5.3.6 Adverse Events of Special Interest
AESIs by Organ System



Pfizer 5.3.6: Women Dominate Every Category of Adverse Events of Special Interest


16



<https://cholecalciferol.substack.com/cp/137040476>

Confirmation: Pfizer Appendix 2.1

ADVERSE EVENTS: APPENDIX 2.1 16-APRIL-2022 N = 1,282,113



Ovaries Concentrate LNP/mRNA More Than Testes


Reports of Female Sexual Dysfunction

(148,874/923,194)

Are More Prevalent

Than Male **(1,745/358,919)**

Uptake in Ovaries vs. Testes



**Female vs. Male Reproductive Disorders (RDs)
After BNT162b2**


| Total # RDs Females | 148,874 of 923,194 AEs | Total # RDs Males | 1745 of 358,919 AEs |
|--------------------------------|------------------------|------------------------------|---------------------|
| RDs as a Percent of Female AEs | 16% | RDs as a Percent of Male AEs | 0.49% |

AEs = Adverse Events






Female vs. Male Reproductive Organ Disorders BNT162b2

Appendix 2.1 April 16, 2022


N = 1,282,113





LNP/modRNA is active at Multiple Sites in Hypothalamic-Pituitary-Ovarian-Uterus System



1,119,610 VAERS Reported Events by Sex and Age, All Age Groups 2021-2022 (2.1)




Change in F:M ratio of Adverse Events by Age: Females 6-29 Years




Women 18-49: 2.6x More Adverse Events and 2-3x Serious AEs in <3 years with C19 GTPs than in 19 Years All Vaccines

#280

**Women Ages 18-49
All Vaccines 1990-2019
Vs
C19 "Vaccines" 2020-2023**



**Serious Adverse Events Doubled or Tripled in
1/6th the Time
Pre Covid (19 years) vs Covid Drugs (<3
years)**



Uterine/Ovarian Dysfunction after BNT162b2 As of 06/18/2022

22


| Dx | N = | # Serious | % of Serious Cases |
|--------------------------|---------|-----------|--------------------|
| Vaginal hemorrhage | 5,034 | 1,334 | 6% |
| Dysmenorrhea | 15,319 | 3,768 | 18% |
| Heavy menstrual bleeding | 30,500 | 6,375 | 30% |
| Menstruation irregular | 16,535 | 2,811 | 13% |
| Menstruation delayed | 15,101 | 2,416 | 11% |
| Menstrual disorder | 24,427 | 2,369 | 11% |
| Amenorrhoea | 12,404 | 1,141 | 5% |
| Polymenorrhea | 10,668 | 896 | 4% |
| Total | 129,988 | 21,111 | |

| Dx | N = | Serious | % Serious |
|--------------------|--------|---------|-----------|
| Excessive Bleeding | 35,534 | 7,709 | 22% |


Spontaneous Abortion : 1990-2020 All Vaccines 2021-2022 C19 Vaxes Only


23

Spontaneous Abortion 1990 - 2022



Spontaneous Abortion 2020-2022





Decline in European Birth Rate in 2022 Following C-19 Inoculation Rollout in 2021


25

- In a population of 159,745,448 Europeans aged 18-49 from 19 countries
 - 71% received 1st C-19 Vacc. 9 months prior to birth rate decline of 7%
 - The rate of vacc had a correlation coefficient = -0.522, p-value = 3.014E-14 with the birth decline (highly statistically significant).
- The higher the rate of vacc., the more the birth rate declined.
- Switzerland witnessed an alarming -8.7% decline
 - Statistical analysis was performed by two independent groups using two different statistical methods with similar findings.

Part 4: CoVax Disease: Organ System x Pathological Process

26

Organ System



Process

- Autoimmunity
- Coagulopathy/Vasculopathy
- Demyelination
- Inflammation
- Neoplasia
- Protein deposition
- Immunological disorder

[J Clin Neurosci](#). 2023 Feb; 108: 37–75. PMID: PMC9780646
Published online 2022 Dec 23. doi: [10.1016/j.jocn.2022.12.015](#) PMID: [36586226](#)

Co-VAN study: COVID-19 vaccine associated neurological diseases- an experience from an apex neurosciences centre and review of the literature

[M.M. Samim](#), [Debjyoti Dhar](#), [Faheem Arshad](#), [D.D.S. Anudeep](#), [Vishal G. Patel](#), [Sriram Ramalakshmi Neeharika](#), [Kamakshi Dhamija](#), [Chowdary Mundlamuri Ravindranath](#), [Ravi Yadav](#), [Pritam Raja](#), [M. Netravathi](#), [Deepak Menon](#), [Vikram V. Holla](#), [Nitish L. Kamble](#), [Prasad K. Pal](#), [Atchayaram Nalini](#), and [Seena Vengalil](#)

Urological-CoVax

28 Types of Urological & Renal Disease

27

Vudathaneni NK, Nadella SB, Hema D, Boyapati R. Renal complications following COVID-19 vaccination: A narrative literature review. *Indian J Community Med* 2023;48:214-9.

Review Article



Renal Complications Following COVID-19 Vaccination: A Narrative Literature Review

Vijaya Krishna Prasad Vudathaneni, Swetha Bharathi Nadella¹, Duddukuri Hema², Ramanarayana Boyapati³

Department of Medicine, Albert Einstein College of Medicine, New York, USA, ¹Baystate Medical Center, 759 Chestnut St, Springfield, MA, USA, ²Mamata Dental College, Giriprasad Nagar Colony, Khammam, Telangana, India, ³Department of Periodontology, Sibar Institute of Dental Sciences, Takkellapadu, Guntur, Andhra Pradesh, India

Multisystem Inflammatory Disease - Children: (MIS-C) 0-17 years: There Were NO Cases before 2021

28



14 y/o Female: BNT162b2 x 3 Sports: Middle School Athletic Team

29


- 9/12/2021: Dose 1 → Arm Pain, No Fever
- 10/3/2021: Dose 2 → Missed 1 Day of School, Fever < 38°C
- 8/10/2022: Dose 3 → Day After Fever = 37.9 °C
 - Difficulty Breathing during night
 - Next AM Mother Found Child Not Breathing
 - Died 45 Hours After Third BNT162b2

<https://doi.org/10.1016/j.legalmed.2023.102244>

Eight Organs: Inflammatory cells including CD3-positive T-cells and CD68 Infiltrating Macrophages

30

14 y/o girl




Nushida, et. al., <https://doi.org/10.1016/j.legalmed.2023.10244>

With Permission

Normal Heart Muscle (Left) compared with Myocarditis from LNP/mRNA (Right)


5/30/24

31




Columns of normal cardiac muscle are replaced by lymphocyte infiltration and degenerating muscle fibers.

Muscle Cell Nucleus



Acute and Chronic Myocarditis @ 1 Year 22 Year Old Male Athlete

Inflammatory cells



Case 85
M 22 Y
Athlete
1x Ja 1x Co
Death 364/238 d p.i.
by suicide
Right Ventricle

Death by Suicide after he learned the seriousness of his illness

Fibrous tissue replacement of cardiac tissue.

Left Ventricle with Scar Tissue + Ongoing Lymphocytic Infiltrate



Case 85
M 22 Y
Left Ventricle

Dr. Burkhardt

Collection of Abnormal Lymphocytes

5/30/24

37:08 / 1:29:08

rumble

The image is a histological slide of a left ventricle specimen. It shows pink-stained muscle fibers and a central area of scar tissue. A yellow arrow points to a dense cluster of dark-stained cells, identified as abnormal lymphocytes. A blue box in the center of the slide contains the text 'Case 85 M 22 Y Left Ventricle'. To the right of the slide is a small video inset of Dr. Burkhardt. At the bottom of the slide, there is a date '5/30/24', a progress bar showing '37:08 / 1:29:08', and the 'rumble' logo.

In Addition to Cardiac Damage, An Aorta Aneurysm was Developing

34



CoVax Disease and Collateral Damage Suicide 581 Events

35

The Vaccine Adverse Event Reporting System (VAERS) Results

Data current as of 09/15/2023

Request Form Results Map Chart Report About

[Dataset Documentation](#) [Other Data Access](#) [Help for Results](#) [Printing Tips](#) [Help with Exports](#)

Save Export Reset

Quick Options More Options API Options

Top Notes Citation Query Criteria

Messages:


- ▶ **VAERS data in CDC WONDER are updated every Friday. Hence, results for the same query can change from week to week.**
- ▶ **These results are for 569 total events.**
- ▶ **Rows with zero Events Reported are hidden. Use Quick Options above to show zero rows.**

| Symptoms ↓ | → Events Reported ↑↓ | ← Percent (of 569) ↑↓ |
|--------------------|----------------------|-----------------------|
| SUICIDAL BEHAVIOUR | 6 | 1.05% |
| SUICIDAL IDEATION | 514 | 90.33% |
| SUICIDE ATTEMPT | 58 | 10.19% |
| SUICIDE THREAT | 3 | 0.53% |
| Total | 581 | 102.11% |

Dosing Drives VAERS Event Reporting: Monthly Doses and VAERS Events

CDC &
VAERS
Access
06/24/2023

36



| SUMMARY OUTPUT | |
|-----------------------|------------|
| Regression Statistics | |
| Multiple R | 0.8612009 |
| R Square | 0.74166699 |
| Adjusted R Square | 0.7320991 |
| Standard Error | 20333.4909 |
| Observations | 29 |

Consequences: Declining Population, Declining Health

37

- **All cause mortality increased:** 17-20 million deaths worldwide: Rancourt
- **Live Births Decreased:** Average decline of 8-10% in many countries
- **Novel Drug → Novel Disease**
 - **Aggressive:** Turbo cancers rapid onset, nonresponsive
 - **Severe:** Insulin resistant diabetes
 - **Unusual presentation:** FLCs
 - **Multiple organs simultaneously:** MIS-A, MIS-C
 - **Immune compromise:** VAIDS
 - **Birth Defects?**
 - **Heritability?**

To Do:

38

1. **Stop** Use of mRNA Products Immediately.
2. **Pass** Legislation to Halt Censorship and Harassment so Medical and Scientific Professionals Can Study and Help the Injured.
3. **Protect** the Doctor Patient Relationship.
4. **Promote** Open Public Discussion with Expert Panels to Educate the Public and Medical Professionals.
5. **Establish** Centers to Collect patients with ‘vaccine’ harms for study and treatment.

Thank You for Allowing Me to Present the PDAP Women's Health Experience

